Telomere Length and Telomerase Activity Biomarkers for Depression Treatment Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biological or clinical tests to predict the development of depression or the responsiveness of individuals to antidepressant treatments, with many patients experiencing inadequate treatment outcomes and residual symptoms.
Innovation Solution
Measuring telomerase activity and telomere length in subjects to determine suitability for antidepressant treatment, predict treatment response, and assess treatment efficacy, using methods that compare pre-treatment and post-treatment levels to identify suitable candidates and monitor treatment effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antidepressant treatment is administered without biological testing, then treatment can be started immediately, but treatment effectiveness is low and many patients experience inadequate outcomes
Solution Approach 1:
The patent applies preliminary action by measuring telomerase activity and telomere length before initiating antidepressant treatment to predict treatment response in advance. This pre-assessment allows clinicians to identify suitable candidates before treatment begins, avoiding the time loss and ineffective treatments that would otherwise occur through trial-and-error approaches.
Solution Approach 2:
The patent utilizes the body's own biological markers (telomerase activity and telomere length) as self-diagnostic indicators of treatment responsiveness. These endogenous markers naturally reflect cellular aging status and predict treatment outcome without requiring external testing agents or complex diagnostic procedures.
2Measurement precision
If no biological test is used, then diagnostic process is simple, but there is no ability to predict depression development or treatment response
Solution Approach 1:
The patent replaces complex mechanical or clinical diagnostic systems with a biochemical measurement approach. Instead of relying on subjective clinical assessments or complex imaging, the invention uses telomerase activity assays and telomere length measurements—simpler biochemical tests that provide objective, quantifiable predictions of treatment response with high measurement precision.
3Productivity
If antidepressant treatment is administered to all diagnosed patients, then treatment coverage is maximized, but resource utilization is inefficient due to non-responders
Solution Approach 1:
The patent applies local quality by tailoring treatment recommendations to individual patients based on their specific telomerase activity levels and telomere length. Rather than applying a uniform treatment protocol to all patients, the invention identifies distinct subgroups (e.g., patients with telomerase activity below 9.5 units/10,000 cells) and provides personalized treatment guidance, optimizing resource allocation while maintaining adaptability to individual needs.
Data Source
AI summary
The present invention provides methods of determining whether a subject is a suitable candidate for an anti-depressant treatment to alleviate a mood disorder by measuring telomere length and telomerase activity. The present invention also provides methods of assessing the efficacy of an anti-depressant treatment to alleviate a mood disorder and of predicting whether a subject is at risk of developing depression.